OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OptiNose prioritizes XHANCE launch for sinusitis, eyes growth opportunities

OptiNose is focusing on profitability and preparing for the launch of XHANCE for chronic sinusitis, anticipating improved financial performance in 2023.
The company's strategic initiatives include exploring commercial partnerships, optimizing expenses, and evaluating potential sale options, indicating a proactive approach to growth.
While facing challenges in revenue generation and prescription volumes, OptiNose is leveraging strengths in financial stability, market reach, and growth opportunities.

OptiNose reports steady Q1 performance amidst revenue challenges and growth opportunities

OptiNose's Q1 2023 performance showed steady prescription demand and a strategic focus on profitability and growth.
While facing challenges like revenue decline and sales force impact, the company is poised for opportunities in market expansion and successful product launches.
Overall, OptiNose remains optimistic about meeting expectations and future approval, positioning itself for continued success in the pharmaceutical market.

OptiNose reports steady Q2 performance, eyes growth with new indications

OptiNose's Q2 2023 performance showed stable prescription demand and a strategic focus on the potential launch of a chronic sinusitis treatment in 2024.
While facing challenges like slightly lower net revenue and upcoming operating expenses, the company is well-positioned for growth opportunities.
With raised revenue guidance, a clear operating strategy, and ongoing FDA review, OptiNose is poised for potential revenue expansion and market growth.

OptiNose reports stable Q3 revenue, eyes growth through XHANCE launch

OptiNose's Q3 2023 performance showed stability in revenue and improved cost efficiency.
While facing challenges in prescription numbers, the company is strategically positioned for growth.
Opportunities lie in potential market expansion through new indications and partnerships.

OptiNose reports strategic growth in Q4 2023, eyes XHANCE approval

OptiNose's performance in Q4 2023 showcased progress in key areas, with a strategic focus on growth and efficiency. The company's financials reflected a reduction in expenses and a stable product demand, positioning it well for potential XHANCE approval and revenue expansion.

OptiNose reports strong Q1 performance and outlines growth strategies

OptiNose's Q1 2024 performance reflects growth in XHANCE net revenue and a strengthened financial position.
The company's strategic focus on chronic sinusitis launch and improved base business fundamentals bode well for future growth.
Opportunities lie in expanding sales efforts, international partnerships, and new product development for sustained value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

OptiNose, Inc. (NASDAQ:OPTN ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Development Dr. Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Operator Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call.

OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.

Optinose to Present at the 2023 Cantor Global Healthcare Conference

Canadian Solar

DocuSign

Nektar Therapeutics

Energous

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).

5 Top-Ranked Stocks With Rising P/E for Solid Returns

OptiNose (OPTN) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.23 per share a year ago.

OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates

Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from the previous quarter and down 5.4% from the first quarter of 2022. On May 4, 2023, the company announced that the FDA had accepted a supplemental new drug application seeking approval for Xhance as a treatment for chronic sinusitis.

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 YARDLEY, Pa.

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 100,000 shares of its common stock to a new employee as an inducement material for accepting employment with OptiNose. The stock option award was granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.

Optinose to Present at the Jefferies Healthcare Conference

OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call.

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

OptiNose, Inc. (NASDAQ:OPTN ) Q4 2022 Earnings Call March 7, 2023 8:00 PM ET Company Participants Jonathan Neely - VP, IR and Business Development Joe Scodari - Chairman Ramy Mahmoud - Chief Executive Officer Paul Spence - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies David Amsellem - Piper Sandler Operator Good day and thank you for standing by. Welcome to the OptiNose's Fourth Quarter 2022 Earnings Call.

OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors Ramy Mahmoud, MD, MPH appointed CEO and to the Board of Directors

Optinose Announces CEO Transition and Business Update

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer.

Optinose Appoints Paul Spence as Chief Commercial Officer

YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022.

Optinose Announces Departure of Acting Chief Financial Officer

$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before deducting underwriting discounts and commissions and offering expenses payable by Optinose. All shares of common stock and accompanying warrants in the offering are being offered by Optinose. The offering is expected to close on or about November 23, 2022, subject to the satisfaction of customary closing conditions.

News for OptiNose Stock (OPTN)